Retrophin signs research agreement with St Jude Children’s Hospital
Under the agreement, Retrophin will supply funds and a library of replacement therapy compounds to St Jude to test for potential use in the treatment of a rare
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The expanded alliance comprises three components co-development of present and future formulations of migalastat HCl for Fabry disease, commercialisation arrangements for all future Fabry products and increased GSK